Results 21 to 30 of about 13,781 (198)

Mulibrey nanism and immunological complications: a comprehensive case report and literature review

Frontiers in Immunology, 2023
IntroductionMulibrey nanism (MUL) is a rare disorder caused by TRIM37 gene variants characterized by growth failure, dysmorphic features, congestive heart failure (CHF), and an increased risk of Wilms’ tumor.
Andrea Gazzin, Andrea Gazzin, Francesca Pala, Marita Bosticardo, Julie Niemela, Jennifer Stoddard, Eleonora Biasin, Paola Quarello, Diana Carli, Diana Carli, Francesca Ferroni, Ottavia M. Delmonte, Davide Montin, Sergio D. Rosenzweig, Francesco Licciardi, Luigi D. Notarangelo   +15 more
doaj   +1 more source

Reprogramming rather than depleting immunity: Targeting the CD38-NAD⁺ axis in antibody-mediated autoimmunity. [PDF]

Clin Transl Med
Clinical and Translational Medicine, Volume 16, Issue 9, September 2026.
Li H, Wei J, Zhang L.
europepmc   +2 more sources

In-depth blood immune profiling of Good syndrome patients

Frontiers in Immunology, 2023
IntroductionGood syndrome (GS) is a rare adult-onset immunodeficiency first described in 1954. It is characterized by the coexistence of a thymoma and hypogammaglobulinemia, associated with an increased susceptibility to infections and autoimmunity.
Alba Torres-Valle, Alba Torres-Valle, Alba Torres-Valle, Larraitz Aragon, Susana L. Silva, Susana L. Silva, Cristina Serrano, Miguel Marcos, Miguel Marcos, Miguel Marcos, Josefa Melero, Carolien Bonroy, Carolien Bonroy, Pedro Pablo Arenas-Caro, David Monzon Casado, Pedro Mikel Requejo Olaizola, Jana Neirinck, Jana Neirinck, Mattias Hofmans, Mattias Hofmans, Sonia de Arriba, María Jara, María Jara, María Jara, Carlos Prieto, Ana E. Sousa, Álvaro Prada, Jacques J. M. van Dongen, Jacques J. M. van Dongen, Jacques J. M. van Dongen, Martín Pérez-Andrés, Martín Pérez-Andrés, Martín Pérez-Andrés, Martín Pérez-Andrés, Alberto Orfao, Alberto Orfao, Alberto Orfao, Alberto Orfao   +37 more
doaj   +1 more source

Persistent hypogammaglobulinemia after rituximab therapy in pediatric patients, prevalence and clinical outcomes

Clinical Immunology Communications
Hypogammaglobulinemia is a known side effect of rituximab (RTX) in adults, but its prevalence and persistence in children remain underexplored. This retrospective cohort study at a tertiary care center examines the prevalence and clinical outcomes of ...
Susanna P.C. Höppener, Saskia R. Veldkamp, Mark C.H. de Groot, Saskia Haitjema, Julia Drylewicz, Jaap Jan Boelens, Caroline A. Lindemans, Joris van Montfrans, Annet van Royen-Kerkhof, Marc H.A. Jansen   +9 more
doaj   +1 more source

Resistant Widespread Facial Impetigo in a Healthy Infant with Atopic Dermatitis [PDF]

Journal of Clinical and Diagnostic Research, 2018
Atopic Dermatitis (AD) or eczema is a chronic and relapsing, itchy skin inflammatory condition in infancy and childhood. The diagnosis is based on pruritus and an eczematous dermatitis with typical presentation.
Seyed Hesamedin Nabavizadeh, Ali Fazel, Soheila Alyasin, Mohammad Bahadoram, Gholamreza Houshmand   +4 more
doaj   +1 more source

Is Rituximab-Associated Hypogammaglobulinemia Always Linked to B-Cell Depletion?

Children, 2022
We describe a case of a 3-year-old male toddler with a history of severe and refractory warm antibody autoimmune hemolytic anemia (w-AIHA) since early infancy and hypogammaglobulinemia persisting 20 months after rituximab administration (second-line ...
Anthie Damianaki, Marianna Tzanoudaki, Maria Kanariou, Emmanouil Liatsis, Alexandros Panos, Alexandra Soldatou, Lydia Kossiva   +6 more
doaj   +1 more source

Strongyloides Hyperinfection and Hypogammaglobulinemia [PDF]

Clinical and Vaccine Immunology, 2005
ABSTRACT We report strongyloides hyperinfection in two patients with generalized hypogammaglobulinemia from multiple myeloma and nephrotic syndrome, despite a significant strongyloides-specific immunoglobulin G (IgG) response. In contrast to reports on animals, where human IgG was shown to be a protective antibody, our observation suggests ...
Seet, R.C.S., Lau, L.G., Tambyah, P.A.
openaire   +2 more sources

Comparative Effectiveness and Safety of Inebilizumab Versus Rituximab in AQP4‐IgG‐Positive NMOSD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Rituximab (anti‐CD20, RTX) and inebilizumab (anti‐CD19, INE) represent B‐cell‐depleting therapies used for aquaporin‐4 antibody‐positive (AQP4‐IgG+) neuromyelitis optica spectrum disorder (NMOSD); however, direct comparative evidence remains limited.
Jie Lin, Binbin Xue, Dewei Xie, Jia Li, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Ruofan Zhu, Xu Zhang, Junhui Xia, Xiang Li   +11 more
wiley   +1 more source

Case Report: Kidney Transplantation in a Patient With Acquired Agammaglobulinemia and SLE. Issues and Challenges

Frontiers in Medicine, 2021
Lupus nephritis in the context of Systemic Lupus Erythematosus (SLE) is characterized by an unpredicted course with remissions and flare-ups. Among others, it remains a significant cause of end-stage kidney disease (ESKD) in relatively young patients ...
Paraskevi Pavlakou, Marios Papasotiriou, Theodoros Ntrinias, Alexandra Kourakli, Adamantia Bratsiakou, Dimitrios S. Goumenos, Evangelos Papachristou   +6 more
doaj   +1 more source

Disease Course After Anti‐CD20 Discontinuation in Secondary Progressive Multiple Sclerosis—A Multicenter Long‐Term Longitudinal Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To describe long‐term outcomes after anti‐CD20 discontinuation in selected patients with secondary progressive multiple sclerosis (SPMS) who remained without subsequent disease‐modifying therapy (DMT). Methods We retrospectively analyzed data from four centers in Austria and Switzerland.
Ferdinand Otto, Dariia Kliushnikova, Richard Friedrich Radlberger, Sinan Yasaroglu, Tobias Moser, Andrea Harrer, Kitty Kratzer, Wolfgang Hitzl, Christiane Gradl, Martin Schmidauer, Patrick Roth, Harald Hegen, Peter Wipfler   +12 more
wiley   +1 more source